⌘ Services
mob-logo
Contact Quote Order Login / Register
mob-logo
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

RNA-Specific Terminal Caps

Reference guide for mRNA capping (Cap 0/1/2, ARCA, CleanCap), terminal phosphate states (ppp/pp/p), NAD caps, and key 3′ RNA caps. Designed for therapeutic mRNA, vaccines, CRISPR guides, and innate-immunity studies.

ISO 9001:2015 / ISO13485:2016 45+ Years of Expertise U.S.A. Facilities-Texas GLP/GMP-Aligned
Talk to a chemist Request a quote
Overview mRNA Caps (5′) Terminal Phosphate States Non-Canonical 5′ Caps 3′ RNA Caps Related product & Services Design & Strategy Chemistry & QC

Overview

5′ caps protect RNA from exonucleases and tune translation and innate sensing. Cap 1 is standard for therapeutic mRNA, while 5′-triphosphate RNA (pppRNA) is intentionally used to activate RIG-I in immunology. Non-canonical caps such as 5′-NAD appear in bacteria and can be leveraged in synthetic biology. At the 3′ end, cyclic- and mono-phosphate caps modulate ligation and stability workflows.

Stability

m⁷G caps (Cap 0/1/2) increase 5′ stability and translation efficiency.

Immunogenicity

ppp/pp RNA triggers RIG-I; Cap 1 reduces innate sensing for in vivo use.

Manufacturing

Co-transcriptional reagents (CleanCap™) and ARCA simplify GMP workflows.

mRNA Caps (5′)

Canonical eukaryotic-style caps supporting translation and stability. Choose Cap 1 for most therapeutic programs; Cap 2 can further reduce innate sensing in some systems.

Product/Modification Function Applications Notes / Code
Cap 0 (m⁷GpppN) 5′–5′ m⁷G triphosphate cap; translation initiation; base protection. In vitro translation, basic mRNA research. Translation ↑ [Cap0]
Cap 1 (m⁷GpppNm) Cap 0 + 2′-O-Me at first nucleotide; reduces innate sensing. Therapeutic mRNA, vaccines, LNP programs. Immune ↓ [Cap1]
Cap 2 (m⁷GpppNmN) Cap 1 + 2′-O-Me at the second nucleotide; may further reduce innate sensing. Advanced therapeutics; immune-silent designs. Immune ↓↓ [Cap2]
ARCA (Anti-Reverse Cap Analog) Cap analog that prevents reverse incorporation; boosts translation. Co-transcriptional capping for IVT mRNA. Orientation-safe [ARCA]
CleanCap™ (series) Co-transcriptional capping reagents; high efficiency Cap 1/2. GMP mRNA manufacturing, high yield capping. Co-Tx [CleanCap]
Hide Technical Notes
  • Recommendation: Default to Cap 1 for in vivo delivery; evaluate Cap 2 in sensitive models.
  • Poly(A) length, UTRs, and base chemistry (Ψ/5-MeC/2′-OMe) co-determine translation and immunogenicity.
  • QC: Verify capping efficiency (LC-MS/enzymatic assays); confirm dsRNA content < threshold.

Terminal Phosphate States (5′)

Uncapped or processed 5′ ends used for innate-immunity probes or enzymology workflows.

Product/Modification Function Applications Notes / Code
5′-Triphosphate (pppN) Strong RIG-I agonist; modest protection vs. exonucleases. Immune stimulation, vaccine adjuvant studies. RIG-I ↑ [5′-ppp]
5′-Diphosphate (ppN) Decapping intermediate; immune-stimulatory. Innate sensing research. Innate ↑ [5′-pp]
5′-Monophosphate (pN) Processed RNA; ligation-ready for many enzymes. Small RNA cloning, turnover studies. Ligation [5′-p]
Show Technical Notes
  • Safety: Avoid 5′-ppp in therapeutic products unless immunostimulation is intended; enzymatically cap or phosphatase-treat.
  • Enzymes: RppH/PNK workflows convert ends between ppp/pp/p for cloning and library prep.

Non-Canonical 5′ Caps

Alternative metabolites used as 5′ caps in bacteria/archaea or synthetic biology contexts.

Product/Modification Function Applications Notes / Code
5′-NAD Cap Nicotinamide adenine dinucleotide covalently linked at 5′. Prokaryotic RNA regulation; synthetic circuits; innate sensing. Non-canonical [NAD-Cap]
Show Technical Notes

NAD capping can alter degradation pathways; evaluate compatibility with ligases and cap-binding proteins prior to workflow design.

3′ RNA Caps

Common 3′ terminal states used for stability or library construction.

Product/Modification Function Applications Notes / Code
2′,3′-Cyclic Phosphate (>&!) Blocks extension; forms during RNase-mediated cleavage. RNA ligation workflows (RtcB), degradation mapping. Block [2′3′-cPO₄]
3′-Phosphate Prevents polymerase extension; convertible to 3′-OH. Blocking, controlled ligation, cloning prep. Block [3′-PO₄]
3′-Amino Provides reactive handle; also blocks natural extension. Conjugation, surface coupling, probe construction. Conjugation [3′-NH₂]
3′-Biotin Affinity capture and detection; terminal block. Pull-downs, ELISA/ISH, library selections. Affinity [Bio-3′]
Show Technical Notes
  • Ligation tips: 2′,3′-cPO₄ is compatible with RtcB; for standard ligases convert to 3′-OH.
  • Blocking: 3′-PO₄ / 3′-NH₂ stop extension and 3′ exonucleases in many systems.

Design & Strategy

Therapeutic mRNA Defaults

  • Use Cap 1, optimized UTRs, poly(A) 80–120 nt, and modified bases (Ψ/5-MeC) as required.
  • Minimize dsRNA impurities; apply HPLC or cellulose purification as needed.
  • Confirm capping efficiency >95% before LNP formulation.

Immunology & Tools

  • Choose 5′-ppp/pp RNA to probe RIG-I pathways; include sequence-matched Cap 1 controls.
  • For ligations, normalize 5′/3′ end states with PNK/RppH/RTCB workflows.

Chemistry & QC

Chemistry

  • Co-transcriptional capping (CleanCap™ series) and enzymatic capping services.
  • Terminal conversions between ppp/pp/p; 3′ end conversions (cPO₄/PO₄/OH).
  • Conjugations: 3′-biotin, 3′-amine; 5′-handles on guides as requested.

QC & Documentation

  • Capping efficiency assays; HPLC/LC-MS identity & purity; dsRNA quantitation.
  • Endotoxin, microbial limits, moisture/salt, and residual DNA as scoped.
  • COA with OD/µmol, method parameters, impurity profile.

FAQ

Cap 1 vs Cap 2—when to choose?
Cap 1 is the default for human therapeutics. Test Cap 2 if innate sensing remains elevated or in specific cell types where additional 2′-O-methylation helps.
Can I intentionally keep 5′-ppp?
Yes, for RIG-I activation studies. For any therapeutic product, remove ppp (or re-cap) to reduce immunogenicity and increase stability
Do 3′ caps affect ligation?
Yes. 2′,3′-cPO₄ requires RTCB-type ligases; convert to 3′-OH for standard T4 ligase reactions.
More FAQ'sAll FAQ's

Need guidance selecting the right RNA cap?

We’ll recommend capping, end-state conversions, and QC panels aligned to your delivery and indication.

Speak to a Scientist Browse All Modifications

Speak to a Scientist

Tell us about your RNA capping project

Full Name *
Email *
Company / Institution *
Phone *
RNA Type
Scale / Quantity
Desired Cap
Terminal States
Purification
QC Requirements
Project Summary *Please avoid confidential details; we can arrange an NDA if needed.

By submitting, you agree to be contacted regarding your request.

972-420-8505 (USA) 800-227-0627 (INTL.) info@biosyn.com Contact Us

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45 years of delivering high-quality, fast, and scalable synthetic biology solutions.

Greetings, Researchers,

Please be advised that any information, guidelines, write-ups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the design of products intended for their experiments before submitting
their designs to Biosynthesis for production feasibility review.
Thank you for your understanding.

Quick Links